Colin Bristow
Stock Analyst at UBS
(1.13)
# 3,577
Out of 4,869 analysts
99
Total ratings
32.76%
Success rate
-13.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $2.70 | +85.19% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $0.48 | +106.48% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $15.80 | +7.63% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $289.33 | +10.25% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.20 | +233.33% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $3.06 | +128.76% | 2 | Feb 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $586 → $583 | $440.87 | +32.24% | 14 | Feb 11, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $23.97 | +16.81% | 13 | Feb 5, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $79.06 | +51.78% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $50.20 | +41.43% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $96 | $108.50 | -11.52% | 3 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $127.04 | +59.01% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.60 | +900.00% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $509.72 | +115.61% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $20.08 | +731.67% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $762.73 | -44.93% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.21 | -37.69% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.66 | +2,626.86% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $185.30 | -21.21% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $46.86 | +60.05% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.42 | +1,730.99% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.75 | +89.47% | 1 | Aug 23, 2021 |
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $2.70
Upside: +85.19%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.48
Upside: +106.48%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $15.80
Upside: +7.63%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $289.33
Upside: +10.25%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.20
Upside: +233.33%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $3.06
Upside: +128.76%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $586 → $583
Current: $440.87
Upside: +32.24%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $23.97
Upside: +16.81%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $79.06
Upside: +51.78%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $50.20
Upside: +41.43%
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $108.50
Upside: -11.52%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $127.04
Upside: +59.01%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.60
Upside: +900.00%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $509.72
Upside: +115.61%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $20.08
Upside: +731.67%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $762.73
Upside: -44.93%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.21
Upside: -37.69%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $0.66
Upside: +2,626.86%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $185.30
Upside: -21.21%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $46.86
Upside: +60.05%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.42
Upside: +1,730.99%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.75
Upside: +89.47%